Pre-infected Immune Effector Cells for Oncolytic Virus Tumor Penetration
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies, including chemotherapy and viral-based approaches, face limitations such as drug resistance, severe side effects, and inefficient tumor targeting, necessitating a more effective local therapy that can selectively kill tumor cells with minimal impact on normal cells.
Innovation Solution
Administering pre-infected immune effector cells, such as cytokine-induced killer cells or tumor-infiltrating T lymphocytes, with replication-competent oncolytic viruses that selectively target and replicate within tumor cells, enhancing biodistribution and cytotoxic effects within tumors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Object-affected harmful factors
If replication-incompetent viruses are used to prevent damage to non-tumor cells, then safety is improved, but viral spread and tumor penetration are limited
Solution Approach 1:
The virus is engineered with segmented functionality: replication-competent genes are separated from tumor-selective genes. The virus can replicate only in tumor cells that express specific markers, creating a segmented control system that enables both safety and effectiveness
Solution Approach 2:
The virus is modified to have localized replication capability - it can replicate selectively in tumor cells with specific surface markers while remaining non-replicating in normal cells. This local quality differentiation allows the virus to spread effectively within tumors without damaging surrounding healthy tissue
2Productivity
If chemotherapy agents are used to treat cancer, then tumor cell killing is achieved, but severe side effects occur
Solution Approach 1:
The oncolytic virus acts as an intermediary that selectively delivers therapeutic effects to tumor cells. The virus infects and replicates in tumor cells, causing their lysis and releasing viral particles that continue to spread, while normal cells remain unaffected due to lack of specific viral receptors or replication-deficient conditions
Solution Approach 2:
The virus is engineered to be self-replicating within tumor cells, eliminating the need for continuous external administration. The virus autonomously replicates and spreads through the tumor, providing sustained therapeutic effect without requiring repeated dosing that would increase systemic side effects
3Productivity
If replication-conditional viruses are used to spread to tumor cells, then tumor penetration is improved, but risk of systemic infection increases
Solution Approach 1:
The virus is engineered with tumor-specific replication conditions - it can replicate only in cells expressing particular surface markers or metabolic characteristics found in tumors. This local quality control ensures the virus spreads effectively within the tumor microenvironment while remaining inert in normal systemic tissues
Solution Approach 2:
The virus is pre-modified with tumor-selective genetic elements before administration. These preliminary modifications include tumor-specific promoters, receptor-targeting modifications, or replication-deficient constructs that are complemented only in tumor cells, ensuring the virus is primed for selective tumor penetration without systemic infection risk
Data Source
AI summary
Compositions and methods are provided for the treatment of cancer. An immune effector cell population is pre-infected with an oncolytic virus. The combined therapeutic is safe and highly effective, producing an enhanced anti-tumor effect compared to either therapy alone. The methods of the invention thus provide for a synergistic effect based on the combined biotherapeutics.